Targeting Clostridioides difficile: New uses for old drugs

J Chen, Y Li, S Wang, H Zhang, Y Du, Q Wu… - Drug Discovery …, 2022 - Elsevier
Clostridioides difficile bacteria can cause life-threatening diarrhea and colitis owing to
limited treatment options and unacceptably high recurrence rates among infected patients …

Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo

GA Naclerio, NS Abutaleb, D Li… - Journal of medicinal …, 2020 - ACS Publications
Clostridioides difficile is the leading cause of healthcare-associated infection in the US and
considered an urgent threat by the Centers for Disease Control and Prevention (CDC). Only …

Exploring novel microbial metabolites and drugs for inhibiting Clostridioides difficile

AA Abouelkhair, MN Seleem - Msphere, 2024 - journals.asm.org
Clostridioides difficile is an enteric pathogen that can cause a range of illnesses from mild
diarrhea to pseudomembranous colitis and even death. This pathogen often takes …

[HTML][HTML] Frontiers in antibiotic alternatives for Clostridioides difficile infection

M Phanchana, P Harnvoravongchai… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Clostridioides difficile (C. difficile) is a gram-positive, anaerobic spore-forming bacterium and
a major cause of antibiotic-associated diarrhea. Humans are naturally resistant to C. difficile …

Antisense inhibition of RNA polymerase α subunit of Clostridioides difficile

R Pal, MN Seleem - Microbiology Spectrum, 2023 - Am Soc Microbiol
Clostridioides difficile, the causative agent of antibiotic-associated diarrhea and
pseudomembranous colitis, has emerged as a major enteric pathogen in recent years …

Discovery of a novel natural product inhibitor of Clostridioides difficile with potent activity in vitro and in vivo

R Pal, MN Seleem - Plos one, 2022 - journals.plos.org
Clostridioides difficile infection is a global health threat and remains the primary cause of
hospital-acquired infections worldwide. The burgeoning incidence and severity of infections …

Discovery of Prenyltransferase Inhibitors with In Vitro and In Vivo Antibacterial Activity

J Song, SR Malwal, N Baig… - ACS Infectious …, 2020 - ACS Publications
Cis-prenyltransferases such as undecaprenyl diphosphate synthase (UPPS) and
decaprenyl diphosphate synthase (DPPS) are essential enzymes in bacteria and are …

Alimentary and Pharmaceutical Approach to Natural Antimicrobials against Clostridioides difficile Gastrointestinal Infection

M Tortajada-Girbés, A Rivas, M Hernández… - Foods, 2021 - mdpi.com
Incidence of Clostridioides difficile infection (CDI) has been increasing in recent decades
due to different factors, namely (i) extended use of broad-spectrum antibiotics,(ii) …

Screening novel antiviral compounds to treat Clostridioides difficile infections

BJ Stolz, AA Abouelkhair, MN Seleem - PloS one, 2024 - journals.plos.org
Clostridioides difficile is a major cause of nosocomial infections, often associated with
individuals who have gut dysbiosis from previous antibiotic therapies. C. difficile infections …

De novo design of a mechano-pharmaceutical screening platform against formation of individual beta-amyloid oligomers

S Pandey, MB Danielsen, Y Xiang, Z Zhang… - Cell Reports Physical …, 2024 - cell.com
Small molecules that can reduce the neurotoxic beta-amyloid (Aβ) aggregates in the brain
provide a potential treatment for Alzheimer disease (AD). Most screening methods for small …